Recombinant multivalent influenza viruses
AssigneeWisconsin Alumni Research Foundation (WARF)
InventorsYoshihiro Kawaoka, Gabriele Neumann
Life of this patent
Estimating the term…
Abstract
The invention provides a composition useful to prepare influenza vaccine viruses, e.g., in the absence of helper virus, which includes internal viral segments from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, and encodes a heterologous antigen.
Claims16
A composition for intranasal delivery comprising an amount of an isolated, single cycle, multivalent recombinant influenza virus having at least seven viral segments selected from influenza virus PA, PB1, PB2, NP, NS, M, HA or NA viral segments, or having at least six viral segments selected from PA, PB1, PB2, NP, NS, M, or HEF viral segments, wherein the NS viral segment comprises coding sequences for an antigenic coronavirus protein, or an antigenic portion thereof, flanked by protease recognition sites, wherein the coding sequences include a receptor binding domain of the coronavirus S protein, wherein the M viral segment comprises a mutant M gene that expresses a functional M1 protein and a mutant M2 protein with a deletion of the cytoplasmic tail and either lacking a transmembrane domain or having a mutated transmembrane domain, wherein the amount is effective to induce a mucosal immune response.
Dependencies are inferred from the claim text.